Lipocine develops oral medicines; partners sell its oral testosterone TLANDO, and its lead candidate, LPCN 1154 (oral brexanolone) for postpartum depression, is not approved.
LPCN 1154, a 48-hour oral brexanolone course for postpartum depression, missed its Phase 3 primary endpoint in April 2026. Post hoc analyses excluding one high-enrolling site with data anomalies suggested benefit, but Lipocine calls them exploratory. After an FDA meeting, it started BLOOM, a placebo-controlled Phase 3 of about 120 patients with tighter site controls; first dosing is expected early in Q4 2026. Cash was $23.3 million at June 30, which Lipocine expects to fund BLOOM at about $1 million a month.
Thesis checklist
0 risks need attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: BLOOM shows a benefit in the full population
Does LPCN 1154 significantly improve HAM-D at 60 hours versus placebo in BLOOM's full population?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
Oral brexanolone's first Phase 3 missed; the new BLOOM trial must show it works
Oral brexanolone's second Phase 3 swing at PPD, with BLOOM's site-controlled design the only test of whether the first miss was noise or signal
Oral brexanolone's PPD Phase 3 miss turns on whether FDA accepts a site-exclusion subgroup as a viable path forward
LPCN 1154's PPD thesis hinges on whether FDA accepts a post hoc subgroup as the basis for regulatory advancement after a full-population Phase 3 miss
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Neurology and pain, Psychiatric disorders, Liver and digestive diseases, Obesity, diabetes and heart disease, Endocrine and bone diseases
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
14 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.